EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563
Recruiting
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Southern California, Los Angeles, California +31 locations
Conditions: Glioblastoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Pa0016 50662, Gilbert, Arizona +130 locations
Conditions: Psoriatic Arthritis
Register for Updates
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
NCT06662188
Recruiting
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3 haploinsufficiency resulting from SHANK3 loss of function mutations and chromosomal deletions encompassing the SHANK3 gene. Clinical data will be evaluated for safety, tolerability, and preliminary clinical activity of JAG201 in pediatri... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
06/05/2025
Locations: Rush University, Chicago, Illinois +2 locations
Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Register for Updates
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073
Recruiting
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments. This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Nova Clinical Research, Bradenton, Florida +3 locations
Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Register for Updates
A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
NCT06734208
Recruiting
This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: Orlando Clinical Research Center, Orlando, Florida
Conditions: Hepatic Impairment
Register for Updates
Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
NCT06788535
Recruiting
The purpose of this Phase 3, open label, single dose imaging study is to evaluate the efficacy and safety of I-124 evuzamitide (radioactive dye) for diagnosing Cardiac Amyloidosis in participants with suspected Cardiac Amyloidosis. The imaging test that will be used in this study is a Positron Emission Tomography Computed Tomography (PET/CT) scan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: City of Hope - Duarte, Duarte, California +11 locations
Conditions: Cardiac Amyloidosis
Register for Updates
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT06855706
Recruiting
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Register for Updates
Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT06912633
Recruiting
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) compared to sham-treated controls.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/05/2025
Locations: California Retina Consultants, Bakersfield, California +3 locations
Conditions: Retinitis Pigmentosa
Register for Updates
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
NCT06989099
Recruiting
To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphedema
Register for Updates
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
NCT00242723
Recruiting
Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein. * Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in patients. * A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them. Objectives: * To evaluate people wi... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, Lung Cancer NOS, Thoracic Cancers, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura
Register for Updates
Genetics of Inherited Eye Disease
NCT02471287
Recruiting
Background: Research has identified some of the genes involved in inherited eye diseases. But for many of these diseases, the genes are not yet known. Researchers want to try to find these genes. They also hope to learn more about how symptoms differ in people with similar gene changes. Objective: To learn more about genes involved in eye diseases. Eligibility: People who have a known or suspected inherited eye disease, and their relatives. Design: * All participants will have a medical h... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Genetic Eye Disease
Register for Updates
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
NCT03762395
Recruiting
The main purpose of this Phase 2 double blind, placebo controlled crossover clinical study is to demonstrate the efficacy and safety of CXA-10 in obese adult asthmatics. Obesity induces a chronic systemic inflammatory state characterized by impaired adipokine signaling, pro-inflammatory cytokine responses, inflammatory cell activation and enhanced generation of oxidative inflammatory mediators. This impacts the lung, increasing the severity of asthma and its exacerbations. This research will eva... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Asthma, Obesity
Register for Updates